SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David Israel-Rosen who wrote (1370)10/9/1998 9:04:00 PM
From: Timothy Kross  Read Replies (1) of 1491
 
There are several thoughts that I have about the design of phase III study for Hu 211. First, I believe that the chance to maximize therapeutic efficacy will be in administering the drug in a shorter period of time. Looking back on the cardiac thrombolysis studies in acute myocardial infarction, it became clear that earlier administration improved efficacy. I suspect that we could see greater efficacy if the drug is given under two or three hours. This is something that could be pursued. Second, I wonder what dose escalations can be given without toxicity. If we choose the 150 mg dose, how do we know that 200mg or 300 mg might not be even more efficacious with little increase in toxicity. Third, I would hope for the larger numbers of a phase III study to give larger subset analysis
to identify specific subgroups that would benefit most from the drug.

Let's hope that the phase III partner can help design a protocol that would help put HU 211 in the best light.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News